Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapiesResearch in context
- Resource Type
- article
- Source
- EClinicalMedicine, Vol 59, Iss , Pp 101997- (2023)
- Subject
Spinal muscular atrophy Gene therapy Follow-up Longitudinal Safety Medicine (General) R5-920 - Language
- English
- ISSN
- 2589-5370